COMUNICADO: Lenvatinib demuestra un aumento significativo de la supervivencia global en cáncer de tiroides refractario a

Actualizado 08/11/2016 13:20:17 CET

2. Matsui J et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008 Sep 1;14(17) :5459-65.

3. Matsui J et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. 2008 Feb 1;122(3):664-71.

4. Okamoto K, et al. Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization. ACS Med. Chem. Lett 2015;6:89-94

5. SmPC Lenvima (updated May 2015). Available at: http://www.medicines.org.uk/emc/medicine/30412 . Accessed: September 2015

6. Schlumberger M et al. Lenvatinib versus placebo in radioiodine refractory differentiated thyroid cancer. NEJM 2015; 372: 621-630. Available at http://www.nejm.org/doi/full/10.1056/NEJMoa1406470 Accessed: September 2015

7. Newbold K et al. Phase 3 study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT): Results and subgroup analysis of patients from Europe. Presented as a digital poster at ETA 2014.

8. Wirth L et al. 2015; Open-Label Extension Phase Outcomes of the Phase 3 Select Trial of Lenvatinib in Patients with 131I-Refractory Differentiated Thyroid Cancer. Endocrine Reviews; 36;2: Abstract 0R44-6. Available at: http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2015.THPTA.6.OR44-6 Accessed: September 2015

9. Schlumberger M et al. Relationship Between Thyroid-Stimulating Hormone Levels and Outcomes from the Randomized, Double-Blind, Phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT). Available at: https://endo.confex.com/endo/2015endo/webprogram/Paper20459.html Accessed: September 2015

10. National Cancer Institute at the National Institute of Health. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/Patient/page1/AllPages#1 . Accessed: September 2015

11. Brito J et al. BMJ 2013; 347

12. Eucan. Thyroid Cancer Factsheet. Available at: http://eu-cancer.iarc.fr/EUCAN/Cancer.aspx?Cancer=35. Accessed: September 2015

13. Cancer Research UK. Thyroid cancer incidence statistics. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/thyroid/incidence/uk-thyroid-cancer-incidence-statistics Accessed: September 2015

14. Gild M et al. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nature Reviews Endocrinology. 2011; 7: 617-624

15. Thyroid Cancer Basics. 2011. Available at: http://www.thyca.org . Accessed: September 2015

16. Pacini F et al. ESMO Guidelines Working Group. Ann Oncol. 2012;23(suppl 7) :vii110-vii119.

17. National Cancer Institue at the National Institute of Health. Available at: http://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq . Accessed: September 2015

18. Ljungberg et al. Guidelines on Renal Cell Carcinoma. Available at: http://uroweb.org/wp-content/uploads/10-Renal-Cell-Carcinoma_LR-LV2-2015.pdf  Accessed: September 2015

 

 

Fecha de preparación: septiembre de 2015 

Código de trabajo: Oncology-UK0047c 

 

CONTACTO: Consultas de los medios de comunicación Eisai Cressida Robson /Ben Speller +44(0)7908 314 155 / +44(0) 7908 409416Cressida_Robson@eisai.netBen_Speller@eisai.net Tonic Life CommunicationsAlex Davies / Emma Coughlan + 44 (0)7720 496 472 / +44 (0)7772 534 646Alex.Davies@toniclc.comEmma.Coughlan@toniclc.com

Para leer más

Europa Press Comunicados Empresas